Literature DB >> 22530761

Sarcopenia in the elderly: basic and clinical issues.

Cuiying Wang1, Li Bai.   

Abstract

The original definition of sarcopenia refers to the age-related loss of muscle mass. The literature suggests that the prevalence of sarcopenia in 60- to 70-year-olds is in the range of 5-13%. Prevalence estimates increase to 11-50% for the population aged 80 years or older. Estimates by the World Health Organization suggest that there were 600 million people aged 60 years or older in the year 2000, and that this number will increase to 1.2 billion by the year 2025. There are, however, limited published data on serial measures of muscle mass in older subjects to establish the age-related changes in muscle mass and to relate this change with adverse health consequences. This review is focused on the definition, prevalence, symptoms, pharmacy and physical therapy of sarcopenia in older subjects with the aim of promoting the recognition and treatment of age-related sarcopenia in the clinical setting.
© 2012 Japan Geriatrics Society.

Entities:  

Mesh:

Year:  2012        PMID: 22530761     DOI: 10.1111/j.1447-0594.2012.00851.x

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  39 in total

Review 1.  Anorexia of aging and gut hormones.

Authors:  Deniz Atalayer; Nerys M Astbury
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Sarcopenic Obesity: An Appraisal of the Current Status of Knowledge and Management in Elderly People.

Authors:  S Molino; M Dossena; D Buonocore; M Verri
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

3.  Automated assessment of thigh composition using machine learning for Dixon magnetic resonance images.

Authors:  Yu Xin Yang; Mei Sian Chong; Laura Tay; Suzanne Yew; Audrey Yeo; Cher Heng Tan
Journal:  MAGMA       Date:  2016-03-30       Impact factor: 2.310

4.  Sarcopenia and length of hospital stay. Is this a vicious cycle?

Authors:  M C Kizilarslanoglu; M K Kilic; R T Dogrul; F Sumer; H D Varan; M E Kuyumcu; Y Yesil; M Halil
Journal:  Eur J Clin Nutr       Date:  2016-02-24       Impact factor: 4.016

5.  Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy.

Authors:  Noriko Ishii; Yoshinori Iwata; Hiroki Nishikawa; Hirayuki Enomoto; Nobuhiro Aizawa; Akio Ishii; Yuho Miyamoto; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

6.  Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Authors:  Hiroki Nishikawa; Norihiro Nishijima; Hirayuki Enomoto; Azusa Sakamoto; Akihiro Nasu; Hideyuki Komekado; Takashi Nishimura; Ryuichi Kita; Toru Kimura; Hiroko Iijima; Shuhei Nishiguchi; Yukio Osaki
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

Review 7.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

8.  The AMPK-related kinase SNARK regulates muscle mass and myocyte survival.

Authors:  Sarah J Lessard; Donato A Rivas; Kawai So; Ho-Jin Koh; André Lima Queiroz; Michael F Hirshman; Roger A Fielding; Laurie J Goodyear
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

9.  Motor unit changes seen with skeletal muscle sarcopenia in oldest old rats.

Authors:  Theodore A Kung; Paul S Cederna; Jack H van der Meulen; Melanie G Urbanchek; William M Kuzon; John A Faulkner
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-09-28       Impact factor: 6.053

10.  Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson's disease.

Authors:  Tamer Yazar; Hülya Olgun Yazar; Emel Zayimoğlu; Soner Çankaya
Journal:  Neurol Sci       Date:  2018-05-12       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.